Premium
The binding of epidermal growth factor to the human uterus and leiomyomata in women rendered hypooestrogenic by continuous administration of an LHRH agonist
Author(s) -
LUMSDEN M. A.,
WEST C. P.,
BRAMLEY T.,
RUMGAY L.,
BAIRD D. T.
Publication year - 1988
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1988.tb06821.x
Subject(s) - agonist , myometrium , epidermal growth factor , endocrinology , medicine , uterus , leiomyoma , menstrual cycle , receptor , hormone , surgery
Summary. The binding of epidermal growth factor (EGF) to human myometrium and leiomyomata was assessed in a group of women rendered hypo‐oestrogenic with the LHRH agonist Zoladex (ICI118630). The results were compared with those obtained with tissues from women with normal cycles. Tn normal women, the specific binding of radiolabelled [ 125 I] EGF to both myometrial and fibroid homogenates did not vary during the menstrual cycle, but the specific binding of [ 125 I] EGF to fibroid in women treated with LHRH agonist was significantly less than in the untreated group. Since the hypo‐oestrogenic state induced by the agonist is associated with a decrease in fibroid size, the results suggest that the effect of oestrogen on fibroid tissue may partly be mediated by EGF.